3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
12
Sarcoma, Endometrial Stromal
1
Recurrence
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasm Metastasis
1
Endometrial Neoplasms
1
ER+ Breast Cancer
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Cancer Patients
1
Advanced Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
Radiosurgery
79
Capecitabine
77
Oxaliplatin
74
Fluorouracil
69
Bevacizumab
69
Gemcitabine
67
Leucovorin
61
pembrolizumab
53
Nivolumab
53
Paclitaxel
48
Irinotecan
47
Radiotherapy
45
Cisplatin
44
Everolimus
38
Magnetic Resonance Spectroscopy
36
Drug Therapy
36
Docetaxel
36
Cyclophosphamide
35
Cetuximab
35
Ipilimumab
32
Carboplatin
32
Trastuzumab
31
Sunitinib
30
Sorafenib
26
Erlotinib Hydrochloride
25
Doxorubicin
23
Surveys and Questionnaires
20
Surgical Procedures, Operative
20
Specimen Handling
20
Biopsy
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasm Metastasis
×
elacestrant
×
Clear all
NCT06201234
2025-12-01
ELEMENT
GBG Forschungs GmbH
Phase 2
Recruiting
176 enrolled